Pneumococcal 15-Valent Conjugate Vaccine Approved for Pediatric Use
The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application for Vaxneuvance (pneumococcal 15-valent conjugate vaccine) for the prevention of invasive pneumococcal disease in pediatric patients 6 weeks through 17 years of…